DMXAA is a tumor-vascular disrupting agent with an IC50 of 9.46 ¡À 1.7 nM. It attacks the blood supply of a cancerous tumor to cause tumor regression. It has a striking antivascular and in some cases curative effect in experimental tumors. Its action on vascular endothelial cells seems to involve a cascade of events leading to induction of tumour haemorrhagic necrosis. These events include both direct and indirect effects, the latter involving the release of further vasoactive agents, such as serotonin, tumour necrosis factor, other cytokines, and nitric oxide from host cells.

June 21, 2017

prudect name : DMXAA is a tumor-vascular disrupting agent with an IC50 of 9.46 ¡À 1.7 nM. It attacks the blood supply of a cancerous tumor to cause tumor regression. It has a striking antivascular and in some cases curative effect in experimental tumors. Its action on vascular endothelial cells seems to involve a cascade of events leading to induction of tumour haemorrhagic necrosis. These events include both direct and indirect effects, the latter involving the release of further vasoactive agents, such as serotonin, tumour necrosis factor, other cytokines, and nitric oxide from host cells.
DMXAA

Synonyms: VadimezanCAS NO: 117570-53-3Molecular Formula: C₁₇H₁₄O₄Molecular Weight: 282.29Purity: 98% minSolubility: In DMSOStorage: −20°C in stock

AMG-232 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18511567